Evidence map›Paper›PMID 41229729›Full record

ArticleFrontiers in cellular neuroscience2025

Ceftriaxone attenuates Poly I:C-induced neuroinflammation

Xizi Shi, Yesheng Sun, Shirin Hosseini, Fangfang Chen, Thekla Cordes, Kristin Michaelsen-Preusse, Martin Korte

Abstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xizi ShiDepartment of Cellular Neurobiology, Zoological Institute, TU Braunschweig, Braunschweig, Germany.
Yesheng SunDepartment of Cellular Neurobiology, Zoological Institute, TU Braunschweig, Braunschweig, Germany.
Shirin HosseiniDepartment of Cellular Neurobiology, Zoological Institute, TU Braunschweig, Braunschweig, Germany.
Fangfang ChenDepartment of Bioinformatics and Biochemistry, Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Thekla CordesDepartment of Bioinformatics and Biochemistry, Braunschweig Integrated Centre of Systems Biology (BRICS), Technische Universität Braunschweig, Braunschweig, Germany.
Kristin Michaelsen-PreusseDepartment of Cellular Neurobiology, Zoological Institute, TU Braunschweig, Braunschweig, Germany.
Martin KorteDepartment of Cellular Neurobiology, Zoological Institute, TU Braunschweig, Braunschweig, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Neuroinflammation triggered by viral infections is increasingly recognized as a driving force in neurodegenerative disease, promoting chronic neuronal injury and cognitive decline. A central mechanism in this process is impaired glutamate clearance due to downregulation of the astrocytic glutamate transporter GLT-1 (EAAT2/SLC1A2), which exacerbates excitotoxicity and neuronal death. Methods: In this study, we assessed the neuroprotective effects of the β-lactam antibiotic ceftriaxone-a known upregulator of GLT-1-in an Results and discussion: Poly I:C exposure elicited robust microglial and astrocytic activation and increased levels of TNF-α, IL-6, and IL-10. Concomitantly, we observed significant downregulation of GLT-1, synapse loss, impaired synaptic plasticity, and disrupted amino acid metabolism. A complementary Mendelian randomization analysis of GWAS data revealed that genetically determined alterations in plasma amino acid levels are significantly associated with the risk of five major neurodegenerative disorders, underscoring the role of metabolic dysregulation in disease pathogenesis. Treatment with ceftriaxone effectively reversed the Poly I:C-induced phenotypes: GLT-1 expression, dendritic spine density, and measures of synaptic plasticity were all restored, and abnormalities in amino acid and tricarboxylic acid cycle metabolites normalized. These findings highlight ceftriaxone's multifaceted neuroprotective profile-modulating glutamate homeostasis, preserving synaptic integrity, and rebalancing metabolic pathways-and support its potential as a therapeutic agent to prevent neuronal degeneration in the context of virus-driven neuroinflammation.

Indexed as

ceftriaxoneGWASLTPneuroinflammationPoly I:C

Identifiers

PMID41229729
PMCPMC12602477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.